Lilly's Kisunla does not demonstrate "good value" for UK's NHS

By Yahoo! Finance | Oct 24, 2024 at 04:08 AM EST

Eli Lilly's Alzheimer's drug, Kisunla, faces NICE rejection in the UK due to concerns about cost-effectiveness and uncertainties about long-term benefits. The drug, like Leqembi, targets amyloid plaques but poses challenges with monitoring costs and accessibility.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.